Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Monte Rosa Therapeutics Inc GLUE

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically... see more

NDAQ:GLUE - Post Discussion

Monte Rosa Therapeutics Inc > The MoBot Report
View:
Post by whytestocks on Oct 28, 2024 12:45pm

The MoBot Report

Just In: $GLUE The MoBot Report2024-10-28 12:33:06 ET DENVER, Colo., Oct 28, 2024 ( 247marketnews.com )- MoBot’s recent alerts involved; Monte Rosa (NASDAQ: GLUE ), Novartis (NYSE: NVS ), Trump Media (NASDAQ: DJT ), Evoke Pharma (NASDAQ: EVOK ), Autonomix Medical (NASDAQ: AMIX ), and Bright...GLUE - The MoBot Report
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities